Source: Breathe, 15 (4) 340; 10.1183/20734735.0250-2019
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Lam Nguyen Ho, Thuong Vu Le. Model for predicting EGFR mutation status in lung cancer. Breathe, 15 (4) 340; 10.1183/20734735.0250-2019

Member's Comments

No comment yet.

Related content which might interest you: Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1550-1551 Year: 2012 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1551 Year: 2012 EGFR exon in lung cancer: Survival predictors? Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012 Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis Source: International Congress 2015 – Quality management in lung cancer Year: 2015 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Prognostic  value of  EGFR  genotype  in  EGFR-mutant  non-small  cell lung  cancer Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Prognostic implications of smoking in patients with advanced lung adenocarcinoma excluding positive mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Correlation between EGFR mutations and emphysematous changes in heavy smokers with lung cancer Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013